Erlocip 100 Mg
$141 – $271
Generic Drugs | Erlotinib |
Manufacturer | Cipla Ltd |
Pack Size | Price | Price Per Unit | Qty | Add To Cart |
---|---|---|---|---|
60 Tablet S | $271 | $4.51 | ||
30 Tablet S | $141 | $4.70 |
Erlocip 100 Mg
Erlocip 100 Mg Tablet is an anticancer medicine used for the treatment of non-small cell lung cancer. It is also used in a combination with gemcitabine to treat pancreatic cancer. This medicine is not recommended for use in patients less than 18 years of age.
Drug = Erlotinib
Strength = 100 Mg
Manufacturer = Cipla Ltd.
How To Take
Take Erlocip 100 Mg in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Erlocip 100 Mg is to be taken empty stomach.
Dosage
Erlocip 100 Mg
Erlocip 150 Mg
Side Effects
Burning or tingling sensation
Cough
Diarrhea
Lower back or side pain
Rash
Chills and fever
Blurred vision
Convulsions (seizures)
Chest pain or discomfort
Acid or sour stomach
Hair loss
Loss of appetite
Warning
Do not use the medication within 2 hours of taking an antacid as it may prevent the absorption of the drug.
Immediately proceed to your nearest emergency department if you suffer an allergic reaction. Symptoms usually associated with such a reaction include difficulty breathing or swallowing, chest tightness, swelling, skin rashes, and hives.
Erlocip 100 Mg is not always suitable for all patients. Always consult your health care provider prior to using this medication if you are pregnant, breastfeeding, trying to conceive, using any other medication (prescription or non-prescription), using any herbal products or supplements, or if you have any allergies or other health problems.
The correct dosage and prescription commonly depend on the patient and the condition being treated. Do not adjust your dosage without the approval of your health care provider. This product is only for use as prescribed and instructed.
Uses
Erlocip 100 Mg hydrochloride is a drug used to treat non-small cell lung cancer (NSCLC).
Reviews
There are no reviews yet.